A serum metabolomics-based profile in low bone mineral density postmenopausal women

Takeshi Miyamoto; Akiyoshi Hirayama; Yuiko Sato; Tami Koboyashi; Eri Katsuyama; Hiroya Kanagawa; Hiroya Miyamoto; Tomoaki Mori; Shigeyuki Yoshida; Atsuhiro Fujie; Mayu Morita; Ryuichi Watanabe; Toshimi Tando; Kana Miyamoto; Takashi Tsuji; Atsushi Funayama; Masaya Nakamura; Morio Matsumoto; Tomoyoshi Soga; Masaru Tomita; Yoshiaki Toyama

doi:10.1016/j.bone.2016.10.027

A serum metabolomics-based profile in low bone mineral density postmenopausal women

Takeshi Miyamoto, Akiyoshi Hirayama, Yuiko Sato, Tami Koboyashi, Eri Katsuyama, Hiroya Kanagawa, Hiroya Miyamoto, Tomoaki Mori, Shigeyuki Yoshida, Atsuhiro Fujie, Mayu Morita, Ryuichi Watanabe, Toshimi Tando, Kana Miyamoto, Takashi Tsuji, Atsushi Funayama, Masaya Nakamura, Morio Matsumoto, Tomoyoshi Soga, Masaru TomitaYoshiaki Toyama

Spine and Spinal Cord Surgery

Research output: Contribution to journal › Article › peer-review

38 Citations (Scopus)

Abstract

Osteoporosis is characterized as a metabolic disorder of bone tissue, and various metabolic markers are now available to support its diagnosis and evaluate treatment effects. Substances produced as end products of metabolomic activities are the correlated factors to the biological or metabolic status, and thus, metabolites are considered highly sensitive markers of particular pathological states, including osteoporosis. Here we undertook comprehensive serum metabolomics analysis in postmenopausal women with or without low bone mineral density (low BMD vs controls) for the first time using capillary electrophoresis/mass spectrometry. Among the metabolites tested, 57 were detected in sera. Levels of hydroxyproline, Gly-Gly and cystine, differed significantly between groups, with Gly-Gly and cystine significantly lower in the low BMD group and hydroxyproline, a reported marker of osteoporosis, significantly higher. Levels of TRACP5b, a bone resorption marker, were significantly higher in the low BMD group, supporting the study's validity. Taken together, our findings represent novel metabolomic profiling in low BMD in postmenopausal women.

Original language	English
Pages (from-to)	1-4
Number of pages	4
Journal	Bone
Volume	95
DOIs	https://doi.org/10.1016/j.bone.2016.10.027
Publication status	Published - 01-02-2017

All Science Journal Classification (ASJC) codes

Endocrinology, Diabetes and Metabolism
Physiology
Histology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bone.2016.10.027

Cite this

Miyamoto, T., Hirayama, A., Sato, Y., Koboyashi, T., Katsuyama, E., Kanagawa, H., Miyamoto, H., Mori, T., Yoshida, S., Fujie, A., Morita, M., Watanabe, R., Tando, T., Miyamoto, K., Tsuji, T., Funayama, A., Nakamura, M., Matsumoto, M., Soga, T., ... Toyama, Y. (2017). A serum metabolomics-based profile in low bone mineral density postmenopausal women. Bone, 95, 1-4. https://doi.org/10.1016/j.bone.2016.10.027

@article{81fef2bfb46b489c9028cbd051c06dd8,

title = "A serum metabolomics-based profile in low bone mineral density postmenopausal women",

abstract = "Osteoporosis is characterized as a metabolic disorder of bone tissue, and various metabolic markers are now available to support its diagnosis and evaluate treatment effects. Substances produced as end products of metabolomic activities are the correlated factors to the biological or metabolic status, and thus, metabolites are considered highly sensitive markers of particular pathological states, including osteoporosis. Here we undertook comprehensive serum metabolomics analysis in postmenopausal women with or without low bone mineral density (low BMD vs controls) for the first time using capillary electrophoresis/mass spectrometry. Among the metabolites tested, 57 were detected in sera. Levels of hydroxyproline, Gly-Gly and cystine, differed significantly between groups, with Gly-Gly and cystine significantly lower in the low BMD group and hydroxyproline, a reported marker of osteoporosis, significantly higher. Levels of TRACP5b, a bone resorption marker, were significantly higher in the low BMD group, supporting the study's validity. Taken together, our findings represent novel metabolomic profiling in low BMD in postmenopausal women.",

author = "Takeshi Miyamoto and Akiyoshi Hirayama and Yuiko Sato and Tami Koboyashi and Eri Katsuyama and Hiroya Kanagawa and Hiroya Miyamoto and Tomoaki Mori and Shigeyuki Yoshida and Atsuhiro Fujie and Mayu Morita and Ryuichi Watanabe and Toshimi Tando and Kana Miyamoto and Takashi Tsuji and Atsushi Funayama and Masaya Nakamura and Morio Matsumoto and Tomoyoshi Soga and Masaru Tomita and Yoshiaki Toyama",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2017",

month = feb,

day = "1",

doi = "10.1016/j.bone.2016.10.027",

language = "English",

volume = "95",

pages = "1--4",

journal = "Bone",

issn = "8756-3282",

publisher = "Elsevier Inc.",

}

Miyamoto, T, Hirayama, A, Sato, Y, Koboyashi, T, Katsuyama, E, Kanagawa, H, Miyamoto, H, Mori, T, Yoshida, S, Fujie, A, Morita, M, Watanabe, R, Tando, T, Miyamoto, K, Tsuji, T, Funayama, A, Nakamura, M, Matsumoto, M, Soga, T, Tomita, M & Toyama, Y 2017, 'A serum metabolomics-based profile in low bone mineral density postmenopausal women', Bone, vol. 95, pp. 1-4. https://doi.org/10.1016/j.bone.2016.10.027

TY - JOUR

T1 - A serum metabolomics-based profile in low bone mineral density postmenopausal women

AU - Miyamoto, Takeshi

AU - Hirayama, Akiyoshi

AU - Sato, Yuiko

AU - Koboyashi, Tami

AU - Katsuyama, Eri

AU - Kanagawa, Hiroya

AU - Miyamoto, Hiroya

AU - Mori, Tomoaki

AU - Yoshida, Shigeyuki

AU - Fujie, Atsuhiro

AU - Morita, Mayu

AU - Watanabe, Ryuichi

AU - Tando, Toshimi

AU - Miyamoto, Kana

AU - Tsuji, Takashi

AU - Funayama, Atsushi

AU - Nakamura, Masaya

AU - Matsumoto, Morio

AU - Soga, Tomoyoshi

AU - Tomita, Masaru

AU - Toyama, Yoshiaki

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Osteoporosis is characterized as a metabolic disorder of bone tissue, and various metabolic markers are now available to support its diagnosis and evaluate treatment effects. Substances produced as end products of metabolomic activities are the correlated factors to the biological or metabolic status, and thus, metabolites are considered highly sensitive markers of particular pathological states, including osteoporosis. Here we undertook comprehensive serum metabolomics analysis in postmenopausal women with or without low bone mineral density (low BMD vs controls) for the first time using capillary electrophoresis/mass spectrometry. Among the metabolites tested, 57 were detected in sera. Levels of hydroxyproline, Gly-Gly and cystine, differed significantly between groups, with Gly-Gly and cystine significantly lower in the low BMD group and hydroxyproline, a reported marker of osteoporosis, significantly higher. Levels of TRACP5b, a bone resorption marker, were significantly higher in the low BMD group, supporting the study's validity. Taken together, our findings represent novel metabolomic profiling in low BMD in postmenopausal women.

AB - Osteoporosis is characterized as a metabolic disorder of bone tissue, and various metabolic markers are now available to support its diagnosis and evaluate treatment effects. Substances produced as end products of metabolomic activities are the correlated factors to the biological or metabolic status, and thus, metabolites are considered highly sensitive markers of particular pathological states, including osteoporosis. Here we undertook comprehensive serum metabolomics analysis in postmenopausal women with or without low bone mineral density (low BMD vs controls) for the first time using capillary electrophoresis/mass spectrometry. Among the metabolites tested, 57 were detected in sera. Levels of hydroxyproline, Gly-Gly and cystine, differed significantly between groups, with Gly-Gly and cystine significantly lower in the low BMD group and hydroxyproline, a reported marker of osteoporosis, significantly higher. Levels of TRACP5b, a bone resorption marker, were significantly higher in the low BMD group, supporting the study's validity. Taken together, our findings represent novel metabolomic profiling in low BMD in postmenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=84994807449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994807449&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2016.10.027

DO - 10.1016/j.bone.2016.10.027

M3 - Article

C2 - 27989648

AN - SCOPUS:84994807449

SN - 8756-3282

VL - 95

SP - 1

EP - 4

JO - Bone

JF - Bone

ER -

A serum metabolomics-based profile in low bone mineral density postmenopausal women

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this